^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19-targeted antibody-drug conjugate

    Related drugs:
    9d
    A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy (clinicaltrials.gov)
    P2, N=30, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Jan 2026 --> Jan 2030
    Trial completion date • Trial primary completion date
    |
    Zynlonta (loncastuximab tesirine-lpyl)
    1m
    EPCOR+LONCA: Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=26, Recruiting, University of Miami | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epkinly (epcoritamab-bysp) • Zynlonta (loncastuximab tesirine-lpyl)
    3ms
    LOTIS 5: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=440, Active, not recruiting, ADC Therapeutics S.A. | Trial primary completion date: Jun 2025 --> Jan 2026
    Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Zynlonta (loncastuximab tesirine-lpyl)
    3ms
    Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Medical College of Wisconsin | N=33 --> 11 | Trial completion date: May 2026 --> Oct 2027 | Trial primary completion date: May 2026 --> May 2025 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)
    4ms
    Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Apr 2026 | Trial primary completion date: Aug 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Zynlonta (loncastuximab tesirine-lpyl) • Lunsumio (mosunetuzumab-axgb)
    4ms
    Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, University of Alabama at Birmingham | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    clonoSEQ
    |
    Calquence (acalabrutinib) • Zynlonta (loncastuximab tesirine-lpyl)
    4ms
    IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=140, Recruiting, Iksuda Therapeutics Ltd. | Trial completion date: Sep 2027 --> Sep 2028 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    IKS03
    4ms
    LOTIS 7: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) (clinicaltrials.gov)
    P1, N=200, Recruiting, ADC Therapeutics S.A. | Trial completion date: Dec 2026 --> Oct 2027 | Trial primary completion date: Dec 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Gazyva (obinutuzumab) • Zynlonta (loncastuximab tesirine-lpyl) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm)
    5ms
    A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD) (clinicaltrials.gov)
    P1, N=36, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events
    |
    ABBV-319
    7ms
    A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL (clinicaltrials.gov)
    P1/2, N=46, Active, not recruiting, Mitsubishi Tanabe Pharma Corporation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Zynlonta (loncastuximab tesirine-lpyl)
    7ms
    Loncastuximab Tesirine and Rituximab as Bridging Therapy Prior to Standard-of-care CD19 CAR T-cell Therapy in Patients With Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=29, Recruiting, University of Utah | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    Rituxan (rituximab) • Zynlonta (loncastuximab tesirine-lpyl)
    8ms
    Antibody-Directed Cell Internalization of Targeted Covalent Europium Tag Enables In Situ Kinase Labeling and Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Quantification. (PubMed, Anal Chem)
    Based on this strategy, we constructed a multifunctional antibody-targeted covalent Ln tag (Ab-TC-Ln, LTX-VC-Ibt-DOTA-Eu), comprising a cell-permeable monoclonal antibody (Loncastuximab, LTX), a targeted covalent Ln tag (Ibt-DOTA-Eu) for Bruton's tyrosine kinase (BTK), and between them a cathepsin B-cleavable linker (VC). LTX-TC-Ln enables cancer cell recognition, internalization, release of targeted covalent element tags, and specific labeling of Ln to intracellular BTK for ICP-MS quantification. Our work establishes a promising antibody-directed cell internalization strategy for intracellular protein Ln labeling and quantification, which will inspire the development of new ICP-MS approaches toward the quantification of other important protein targets in the future.
    Journal
    |
    BTK (Bruton Tyrosine Kinase)
    |
    Zynlonta (loncastuximab tesirine-lpyl)